Gosset RefleXion Medical General Information
RefleXion Medical has developed the first biology-guided radiotherapy system that uses real-time PET imaging to direct radiation precisely at tumor sites. Its flagship product, the RefleXion X1 with SCINTIX therapy, received FDA clearance in February 2023 for treating lung and bone tumors. Early clinical cases have demonstrated precise targeting of moving tumors while sparing healthy tissue. The company continues expanding access through installations at major cancer centers.
Contact Information
USA
Drug Pipeline
Key Partnerships
Notable investors include Pfizer Ventures, Johnson & Johnson Innovation – JJDC; no explicit pharma/biotech development partnerships disclosed but collaborations with leading academic medical centers such as Stanford Medicine Cancer Center are highlighted.
RefleXion Medical Funding
No funding data available